Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;1529(1):33-41.
doi: 10.1111/nyas.15052. Epub 2023 Aug 18.

Combination chelation therapy

Yesim Aydinok  1
Affiliations
Review

Combination chelation therapy

Yesim Aydinok. Ann N Y Acad Sci. 2023 Nov.

Abstract

Combination chelation therapies are considered in transfusion-dependent thalassemia patients for whom monotherapy regimens have failed to achieve iron balance or intensification of iron chelation therapy is required for the rapid reduction of excess iron to avoid permanent organ damage. Combination chelation may provide a more flexible approach for individualizing chelation therapy, thereby improving tolerability, adherence, and quality of life. In principle, iron chelators can be combined with an infinite number of dosing regimens; these involve simultaneous or sequential exposure to the chelators on the same day or alternating the drugs on different days. Clinical studies have established the safety and efficacy of chelation combinations. However, real-life data with combination therapies indicate the significance of compliance for a meaningful reduction in iron overload compared to monotherapies.

Keywords: deferasirox; deferiprone; deferoxamine; iron chelation; iron overload; thalassemia.

PubMed Disclaimer

References

REFERENCES

    1. Porter, J. B., & Shah, F. T. (2010). Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies. Hematology Oncology Clinics of North America, 24(6), 1109-1130. https://doi.org/10.1016/j.hoc.2010.08.015
    1. Porter, J. B., Evangeli, M., & El-Beshlawy, A. (2011). The challenges of adherence and persistence with iron chelation therapy. International Journal of Hematology, 94(5), 453-460. https://doi.org/10.1007/s12185-011-0927-3
    1. Galanello, R., Agus, A., Campus, S., Danjou, F., Giardina, P. J., & Grady, R. W. (2010). Combined iron chelation therapy. Annals of the New York Academy of Sciences, 1202, 79-86. https://doi.org/10.1111/j.1749-6632.2010.05591.x
    1. Cabantchik, Z., Breuer, W., Zanninelli, G., & Cianciulli, P. (2005). LPI-labile plasma iron in iron overload. Best Practice & Research, Clinical Haematology, 18(2), 277-287. https://doi.org/10.1016/j.beha.2004.10.003
    1. Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., & Cabantchik, Z. I. (2003). Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood, 102(7), 2670-2677. https://doi.org/10.1182/blood-2003-03-0807

LinkOut - more resources